Form 4: Immix Biopharma Director Helen C. Adams Reports Acquisition of Shares Following Merger

Director Helen C. Adams reports acquiring shares of Immix Biopharma, Inc. following the merger with Nexcella, Inc.

Summary

• Helen C. Adams, a director of Immix Biopharma, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 15, 2024, Adams acquired 87,740 shares of common stock as a replacement for prior awards held in Nexcella, Inc., related to the merger.
• These shares were issued as restricted stock awards vesting in thirteen equal monthly installments, contingent on continued service with the Issuer.
• On May 20, 2024, Adams acquired an additional 74,241 shares in exchange for shares of Nexcella, Inc. common stock as part of the merger.
• Following these transactions, Adams beneficially owns 174,754 shares of Immix Biopharma, Inc. common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the director is increasing their stake in the company following a merger, which could be seen as a sign of confidence. However, it's a standard transaction related to the merger agreement.

Positives

• The director's acquisition of shares signals confidence in the company following the merger.

Future Outlook

The restricted stock awards will vest in thirteen equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the director's increased ownership positively.

Key Dates